


InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology

Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based, multi-organ models

SCHLIEREN, ZÜRICH, SWITZERLAND, February 1, 2019 /EINPresswire.com/ --

The February 2019 issue of the scientific journal [SLAS Technology](#) showcases the innovative, scalable microfluidic platform that inspired InSphero's new organ-on-a-chip system: Akura™ Flow. InSphero Head of Technology and Platforms Dr. Olivier Frey and co-authors from Prof. Andreas Hierlemann's bioengineering lab at ETH Zürich were invited to contribute the article for the journal as top finalists for the prestigious SLAS Innovation Award in 2018.



InSphero has been testing and perfecting organ-on-a-chip solutions since 2011, when the company teamed up with ETH, AstraZeneca and other leading academic groups in the EU-supported research project Body-on-a-Chip, that aimed to mimic the response of the human body as a whole to drugs for safety and efficacy testing. Working in collaboration, microfluidics experts at ETH Zürich and InSphero, were able to refine early prototypes of the system and create the basis for a higher order system suitable for applications such as low clearance assays and metabolic disease modeling. InSphero has since been working on commercialization of the Akura™ Flow system to ensure the operational robustness and trustworthy results demanded by the pharmaceutical industry. Akura™ Flow is

“

Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.”

*Olivier Frey, PhD, InSphero
Head of Technology and
Platforms*

also the first technology to address important industry needs, such as short setup times of one week and the capability to automatically extract 3D microtissues from the device for downstream next-gen sequencing, histology or other rich endpoints.



Dr. Frey, who spearheads Akura™ Flow product development, says, “This is truly an exciting time to be working in the field of biomedical microfluidics. In partnership with our customers, we can now develop a wide range of multi-tissue configurations, from tumor-liver-immune system interactions for cancer research to liver-pancreatic islet communications for the study of metabolic diseases, such as diabetes and NASH. Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.”

InSphero will be presenting on Akura™ Flow and 3D human tissue models for drug discovery and development at [SLAS2019](#), Feb 2-6, in Washington, DC. The company will also be participating in the SLAS Exhibition and can be found at booth 848.

To read the SLAS Technology paper, “Scalable Microfluidic Platform for Flexible Configuration of and Experiments with Microtissue Multiorgan Models”, see:

<https://journals.sagepub.com/doi/abs/10.1177/2472630318802582?journalCode=jlad>

To learn more about the Akura Flow organ-on-a-chip system, visit:

<https://insphero.com/science/enabling-technology/microphysiological-systems/>

For more information about InSphero, visit www.insphero.com.

#

Frank Junker, Chief Business Officer

InSphero AG

+41 44 515 04 90

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/475311812>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.